Expect Boston Scientific to Keep Rounding Out Its Portfolio with M & amp;A

 Boston Scientific has been on quite the shopping spree in 2018. The Marlborough, MA-based company has announced eight acquisitions since the beginning of the year, plus a hefty investment in Millipede, which is likely to lead to an acquisition within the next year or so. Naturally, the company's aggressive M&A strategy has attracted attention from industry analysts who are eager to see if this spree will continue in 2019. During the company's third-quarter earnings call on Thursday, CFO Daniel Brennan said Boston Scientific still has a "tremendous amount" of financial flexibility. Looking at 2019 and 2020, Brennan said he expects cash flow to be north of $2 billion in each of those years. "That still gives us ample capacity to be able to continue to execute our strategy, which is category leadership. So, I would look for us to continue to do acquisitions that fill out the portfolio," he said. For the transactions Boston Scientific has announced this year (including the Millipede investment), the company has spent about $1,560 upfront, and agreed to shell out up to $2,432 total once milestone payments are factored in. Here's a quick refresher of the company's deal activity so far this year. 1. Millipede In January, Boston Scientific purchased $90 million in Santa Ana, CA-based Millipede, a company that has developed the Iris transcatheter annuloplasty ring system for the treatment of severe mitral reg...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news